Segment Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) segment	Mar. 31, 2021 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	2
Segment Reporting Information [Line Items]
Total net revenue	$ 117,169	$ 115,533
Total cost of revenue	78,937	73,959
Total gross profit	38,232	41,574
General and administrative	66,248	40,476
Research and development	7,713	2,456
Sales and marketing	16,299	13,749
Total operating expenses	90,260	56,681
Loss from operations	(52,028)	(15,107)
Interest (income) expense, net	1,301	1,177
Other (income) expenses, net	(168)	4,854
Loss before taxes	(53,161)	(21,138)
Income tax (benefit) expense	(3,753)	976
Net loss	(49,408)	(22,114)
Clinical Services
Segment Reporting Information [Line Items]
Total net revenue	98,791	96,487
Total cost of revenue	65,267	61,565
Total gross profit	33,524	34,922
Amortization of acquired intangible assets	4,300
Clinical Services | COVID-19 PCR Testing
Segment Reporting Information [Line Items]
Write off of COVID-19 PCR testing inventory		5,300
Pharma Services
Segment Reporting Information [Line Items]
Total net revenue	18,378	19,046
Total cost of revenue	13,670	12,394
Total gross profit	4,708	6,652
Amortization of acquired intangible assets	$ 600	$ 0